Coenzyme Q10 for Migraine

Verdict: Modest, real benefit for migraine prevention

Coenzyme Q10 appears to modestly reduce how often migraines occur, but the effect is small and the overall evidence is still preliminary, so it is best viewed as an optional add-on rather than a proven, stand-alone treatment.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Two recent meta-analyses anchor the positive signal: Sazali 2021 (PMID 33402403; 6 trials, n=371) found about 1.5 fewer migraine days per month (MD -1.52, 95% CI -2.40 to -0.65, p<0.001) and a small drop in attack duration, while Parohan 2020 (PMID 30727862; 4 trials, n=221) reported roughly 1.9 fewer attacks per month (WMD -1.87, p<0.001). Supporting RCTs (PMID 29298622; PMID 30612463; PMID 25916335) point the same direction.

The grade stays at preliminary rather than strong because the benefit is genuinely modest and inconsistent across endpoints. Both meta-analyses found that attack severity did not improve significantly, several supportive trials were tiny or combined CoQ10 with L-carnitine or riboflavin and magnesium (PMID 30612463; PMID 25916335) rather than testing it alone, and some included studies had drug-manufacturer funding.

Authorities are cautious and not aligned. The US FDA treats disease claims for CoQ10 as unapproved 'new drugs,' the EU EFSA concluded a cause-and-effect relationship has not been established, and the UK NHS/NICE recommends riboflavin for migraine while not listing CoQ10. Mayo Clinic and Cleveland Clinic say it 'might' or 'may' help and note it can take 2-3 months to judge; warfarin users, pregnant or breastfeeding people, and children should use caution.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.60
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.46
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.604
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis
PMID: 33402403 2021 統合分析 n = 371
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Significant reduction in migraine frequency vs control"}, "duration_hours": {"direction": "reduction", "significan
Mixed funding
View on PubMed
Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials
PMID: 30727862 2020 統合分析 n = 221
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Significant reduction in monthly migraine attack frequency"}, "severity": {"direction": "reduction", "significant"
View on PubMed
The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial
PMID: 30612463 2019 隨機對照試驗 n = 56
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Significant reduction in migraine attack frequency vs placebo (combination CoQ10+L-carnitine)"}, "severity": {"dir
View on PubMed
Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers
PMID: 29298622 2019 隨機對照試驗 n = 45
Finding: {"frequency_per_month": {"direction": "reduction", "significant": true, "narrative": "Significant improvements in frequency, severity, and duration; reductions in CGRP and TNF-alpha"}, "severity": {"d
View on PubMed
Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
PMID: 25916335 2015 隨機對照試驗 n = 130
Finding: {"frequency_per_month": {"direction": "reduction", "significant": false, "narrative": "Migraine days/month declined 6.2 -> 4.4 in supplement arm; frequency change vs placebo not the primary significan
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
not generally recognized as safe and effective for the referenced uses and therefore are considered "new drugs" source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established between the consumption of coenzyme Q10 and the claimed effects source↗
L4c UK NHS
Cautious
Advise people with migraine that the food supplement riboflavin (400 mg once a day) may be effective in reducing migraine frequency and intensity for some people. source↗
L4d TW TFDA / 衛福部
Cautious
訂定「食品原料輔酵素Q10 (Coenzyme Q10)之使用限制及標示規定」 source↗
L5b Mayo Clinic
Cautious
CoQ10 might lower how often migraines happen source↗
L5c Cleveland Clinic
Cautious
CoQ10 may help reduce migraine frequency source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-migraine-INT-coenzyme-q10-001 繁體中文版 →